TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05556863
Drug: ELA026
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of ELA026
Study: NCT05051566
Drug: LY3502970
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06438861
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will undergo intradetrusor onabotulinumtoxinA injections of 100U either in the office or in the operating room depending on patient and provider preference. Patients will begin taking vibegron 75mg daily or a placebo pill daily starting the day of their procedure and continue for 3 months.
Study: NCT04829344
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Topical Ophthalmic Solution
Study: NCT04106999
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline will be infused as a control drug
Study: NCT06130059
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05959850
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomised to the control arm will receive a placebo for the duration of the study. The placebo will look and taste like ambroxol, but will have no active ingredient. Participants will not be told which arm they have been randomised to. The placebo will primarily be a glucose solution, however it will also have flavouring (e.g. bitters) and colouring, so as to make it look and taste like ambroxol, to maintain blinding.
Study: NCT05997043
Drug: oral anti-Parkinson's drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group only took oral anti-Parkinson's drugs.
Study: NCT05605119
Drug: AUR105
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily
Study: NCT04826354
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin
Study: NCT06293729
Drug: NGGT006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion of NGGT006 at low dose (7.5e12vg/kg), medium dose (1.5e13vg/kg) and high dose (3e13vg/kg).
Study: NCT05566652
Drug: Pressure Support Ventilation
Approvals — FDA: no, EMA: no, PMDA: no
Description: To evaluate WOB and asynchronies in patients with low respiratory system compliance undergoing either PSV and NPS.
Study: NCT05909332
Drug: Antivascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BP102 (anti VEGFR)
Study: NCT05909332
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: ddEC-P
Study: NCT04696731
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy for lymphodepletion
Study: NCT05748405
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Tablets
Study: NCT05748405
Drug: AEF0217
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets of 100 mcg AEF0217
Study: NCT06578234
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard dose 140 μg/kg/min and high dose 210 μg/kg/min adenosine
Study: NCT03782155
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: powder 17g
Study: NCT06305351
Drug: K-757 and K-833 QD
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both administered orally once daily
Study: NCT06305351
Drug: K-757 and K-833 BID
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both administered orally twice daily
Study: NCT06305351
Drug: Matching placebo to K-757 and K-833 QD
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both administered orally once daily
Study: NCT06305351
Drug: Matching placebo to K-757 and K-833 BID
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both administered orally twice daily
Study: NCT05780645
Drug: ALXN2050 Immediate Release (IR) Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose IR (ALXN2050 Film Coated Tablet) tablet orally.
Study: NCT05780645
Drug: ALXN2050 MR Prototype Mini-Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive various doses of the MR Prototype Mini-Tablet orally.
Study: NCT04298567
Drug: Acetylsalicylic acid(ASA)
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASA (75mg \[QD\]; dose according to local label.
Study: NCT06607276
Drug: Adebrelimab and capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adebrelimab: 1200mg, IV, q3w for one year; capecitabine:1250mg/m2, po, bid,d1-14, q3w, for 6-8 cycles
Study: NCT06607276
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine:1250mg/m2, po, bid,d1-14, q3w, for 6-8 cycles
Study: NCT05465226
Drug: Historical opioid use
Normalized name: Drugs used in opioid dependence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical matched, control group in 2:1 ratio
Study: NCT04761848
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet twice daily
Study: NCT06342596
Drug: [14C]-LY3473329
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06342596
Drug: [14C]-LY3473329
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT06342596
Drug: LY3473329
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04717193
Drug: Rectus Sheath Block with 0.25% bupivicaine with 1:200 000 epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral rectus sheath block plus infiltration local anesthetic at incision sites.
Study: NCT05318105
Drug: IV Loop Diuretics
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: diuretics
Study: NCT05151679
Drug: Chelated Iron
Normalized name: Chelated Iron 15 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment will be started 24rh after initial visit women will be randomized used random sequence computer generated list in such a way that every patient had equal chance to be among any of the two groups either to group 1 , where they will receive I.V ferrous sucrose in the E.U in Women's Health Hospital Assuit University as an i.v infusion in 250 ml 0.9% sodium chloride slowly over 30 minutes.~The total required dose of iron will be divided into three doses, which will be given every 3 days, and the maximum daily dose is 200mg ( 2 ampoules ).
Study: NCT05013450
Drug: PD-1/PD-L1 blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC immunotherapy with PD-1/PD-L1 blockade
Study: NCT05551949
Drug: Vaginal estradiol tablets
Normalized name: estradiol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal estradiol tablets (10mcg).
Study: NCT05010148
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: D5 water given at an equivalent ml/hr as intravenous lidocaine (treatment arm) for 48 hours following major spinal surgery
Study: NCT03734731
Drug: Opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribe Opioids to treat for pain or circulatory disorders, dosage to be determined by Principal Investigator
Study: NCT06344312
Drug: Yangxue Qingnao Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: When receiving intravenous thrombolysis with ateplase, two bags of Yangxue Qingnao Granule Simulator were randomly taken orally. Afterwards, one bag of Yangxue Qingnao Granule/ Simulator was taken three times a day for a total of two weeks.
Study: NCT05378945
Drug: Placebo (vehicle)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal delivery of placebo (vehicle) twice a day (BID) for 28 days
Study: NCT05427669
Drug: mFOLFOXIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles at the most
Study: NCT05427669
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles at the most
Study: NCT03958344
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT06490484
Drug: HSK16149 20mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: HSK16149 20mg BID HSK16149 20mg, orally twice a day; treatment period: 4 weeks fixed dose.
Study: NCT06732245
Drug: NA-931
Approvals — FDA: no, EMA: no, PMDA: no
Description: NA-931 (oral, daily), a quadruple receptor agonist~Tirzepatide (Zepbound) placebo
Study: NCT04656847
Drug: in daily everyday routine practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients with HTN and CAD treated with the the single pill combination bisoprolol/perindopril for 12 weeks in the daily clinical practice Retrospective screening and evaluation of patient's eligibility to inclusion/ exclusion criteria for entering the study allows mitigating a potential risk of deliberative medicine administration within the observational program.
Study: NCT06732245
Drug: NA-931
Approvals — FDA: no, EMA: no, PMDA: no
Description: NA-931, an oral, daily~• A quadruple receptor agonist
Study: NCT06732245
Drug: NA-931
Approvals — FDA: no, EMA: no, PMDA: no
Description: NA-931 (oral, daily), a quadruple receptor agonist~Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound
Study: NCT06732245
Drug: NA-931
Approvals — FDA: no, EMA: no, PMDA: no
Description: NA-931 (oral daily), a quadruple receptor agonist~Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound
Study: NCT04899518
Drug: ALY688 Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic Solution
Study: NCT06174363
Drug: Maxigesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: For postoperative analgesia, 50 mcg of fentanyl was administered 15 minutes before the end of surgery, and IV-PCA (fentanyl 1.0 mcg/kg, ramosetron 0.3 mg, total 250cc, infusion rate 5cc/h, bolus 0.5 cc, lock-out time 15min) is started. Additionally, in the Maxigesic group, one vial of Maxigesic (acetaminophen 1000mg/ ibuprofen 300mg) is administered 15 minutes before the end of the surgery, and 2 vials of Maxigesic are added to the IV-PCA.
Study: NCT06174363
Drug: 0.9% saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: For postoperative analgesia, 50 mcg of fentanyl was administered 15 minutes before the end of surgery, and IV-PCA (fentanyl 1.0 mcg/kg, ramosetron 0.3 mg, total 250cc, infusion rate 5cc/h, bolus 0.5 cc, lock-out time 15min) is started. Additionally, in the control group, the same amount of 0.9% saline solution with Maxigesic is administered.
Study: NCT01947608
Drug: LDK378
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg. orally
Study: NCT05086289
Drug: LY3526318
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05086289
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04982900
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo has the same appearance, weight, and physical and chemical properties as the study drug, and is provided by the researcher to the subjects in control group.
Study: NCT06669299
Drug: Antiarrhythmic Drug Therapy (amiodarone, sotalol, or mexiletine)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients with a positive NIPS already on antiarrhythmic drugs (AAD) before the index procedure will re-start the original antiarrhythmic therapy. Patients who were not on AAD will start a new drug at the operator's discretion (amiodarone, sotalol, or mexiletine) according to clinical practice.
Study: NCT06740240
Drug: 68Ga-FAPI-Biotin
Normalized name: Biotin
DrugBank: Biotin (DB00121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI-Biotin. Tracer doses of 68Ga-FAPI-Biotin will be used to detect tumors by PET/CT
Study: NCT06669429
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo matching tne RS-C1001 dose orally as a single ascending dose
Study: NCT06669429
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo matching tne RS-C1001 dose orally as a multiple ascending dose
Study: NCT06669429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo matching tne RS-C1001 dose orally as a single dose after intake of a high-calorie, high-fat breakfast
Study: NCT06669403
Drug: OPT101
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPT101, is a 15-mer peptide derived from the sequence of mouse CD40L and was designed to target CD40-mediated inflammation. On the day of administration, the product will be diluted in saline to result in 50 mL for intravenous (IV) infusion over 120 minutes.
Study: NCT06224881
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 gm every 8hrs for 4 days
Study: NCT06670352
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD or BID, 24-weeks fixed dose.
Study: NCT06670352
Drug: HSK39297 50mgBID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-weeks fixed dose.
Study: NCT06670352
Drug: HSK39297 100mgBID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-weeks fixed dose.
Study: NCT06670352
Drug: HSK39297 200mgQD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-weeks fixed dose.
Study: NCT06241755
Drug: BCG for Therapeutic Use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specification: 60 mg (6.0×10\^7 CFU)/vial, each vial contains BCG 60 mg and each mg BCG shall have a count of live bacteria not less than 1.0×10\^6 CFU.~Usage \& dosage: Dissolving two vials (120 mg) into 40-50 mL normal saline and shaking thoroughly. Following the procedures of surgical cauterization, inserting a Foley tube into cystic cavity and instilling diluted drug solution. After instillation, constantly changing body positions of a patient, such as left/right recumbent and supine/prostrate. Each position is maintained for around 30 min. Self-discharging drug solution after 2h.
Study: NCT06241755
Drug: BCG for Therapeutic Use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specification: 60 mg/vial with a count of live BCG bacteria not less than 1.0×10\^6 CFU/mg.~Usage \& dosage: Dissolving two vials (120 mg) into 40-50 mL normal saline and shaking thoroughly. Following the procedures of surgical cauterization, inserting a Foley tube into cystic cavity and instilling diluted drug solution. After instillation, constantly changing body positions of a patient, such as left/right recumbent and supine/prostrate. Each position is maintained for around 30 min. Self-discharging drug solution after 2h.
Study: NCT06080776
Drug: Placebo SH-1028 tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo SH-1028 tablets.
Study: NCT05321498
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be delivered by subcutaneous injection once a week
Study: NCT05386888
Drug: GFH018
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as oral
Study: NCT05386888
Drug: GFH018
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an IV infusion
Study: NCT06192680
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m² PO BID
Study: NCT06017583
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral capecitabine 825mg/m2 bid, radiotherapy day concurrent chemotherapy. Chemotherapy regimen after radiotherapy: XELOX regimen: oxaliplatin intravenous infusion of 130mg/m2/d1+ oral capecitabine 1000mg/m2 bid/ d1-14, 21 days per cycle, at least 2 cycles completed.
Study: NCT06191887
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05140954
Drug: co-formulated 25mg TAF/ 200mg FTC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized into 1 of 3 groups to receive a controlled number of doses of a single tablet co-formulated 25 mg TAF/ 200mg FTC
Study: NCT05394740
Drug: CapeOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: For Cohort A only~* Capecitabine 1,000 mg/m\^2 administered orally, twice daily (Days 1 to 14 continuous dosing of CapeOX therapy)~* Oxaliplatin 130 mg/m\^2 administered intravenously (Day 1 of CapeOX therapy) \*Repeat every 3 weeks as CapeOX therapy
Study: NCT05394740
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: For Cohort B only~* Leucovorin 400 mg/m\^2 administered intravenously (Day 1 of FOLFOX therapy)~* Fluorouracil 400 mg/m\^2 administered intravenously (Day 1 of FOLFOX therapy) and 1,200 mg/m2 administered intravenously (Days 1 to 2 of FOLFOX therapy)~* Oxaliplatin 85 mg/m\^2 administered intravenously (Day 1 of FOLFOX therapy) \*Repeat every 2 weeks as FOLFOX therapy
Study: NCT06166914
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After informed consent, children under 14 years of age with high-risk PRRD underwent pars plana vitrectomy and silicone oil injection with scleral buckle divided into 2 groups in prospective randomized trial. Group B received infusion of normal saline.
Study: NCT05582265
Drug: Carboplatin (neoadjuvant）
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Study: NCT05582265
Drug: Carboplatin (adjuvant）
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Study: NCT05981768
Drug: Cytisinicline
Normalized name: cytisinicline
Approvals — FDA: no, EMA: no, PMDA: no
Description: film-coated oral tablets containing 3 mg cytisinicline
Study: NCT05772546
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose monohydrate, tablet taken orally.
Study: NCT05763160
Drug: RZL-012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ready to use drug product for injection into the subcutaneous fat
Study: NCT05491694
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600mg/m2，IVD，q3w
Study: NCT05244473
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV
Study: NCT05298696
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily
Study: NCT05403580
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03911336
Drug: Group A - test:Tooth extraction and intake of NSAID and a non-NSAID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 AM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
Study: NCT03911336
Drug: Group C - Control 2: tooth extraction and intake of a Non-Nsaid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tooth extraction and intake of a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8AM, 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
Study: NCT04811469
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral solution, given once
Study: NCT06214572
Drug: Systemic therapy (Gemcitabine plus Cisplatin)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive one of the following Gemcitabine-based systemic therapy alone:~Gemcitabine 1000mg/m2 and Cisplatin 25 mg/m2, each administered on Days 1 and 8 every 3 weeks (q3w)~Duration: 3 months (in addition to 3 months previously received)
Study: NCT06214572
Drug: Systemic therapy (Gemcitabine plus oxaliplatin)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m2 and oxaliplatin 100 mg/m2 IV infusion on days 1 and 8 q2w.~Duration: 3 months
Study: NCT06214572
Drug: Systemic therapy (Gemcitabine plus Cisplatin plus Durvalumab)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab 1500 mg via intravenous (IV) infusion q4w, starting on Cycle 1 in combination with cisplatin 25 mg/m2 and gemcitabine 1000 mg/m2 each administered on Days 1 and 8, q3w.~Duration 3 months Durvalumab (12 months)
Study: NCT06214572
Drug: Systemic therapy (Gemcitabine plus cisplatin plus nab-paclitaxel)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 800 mg/m2, cisplatin, 25 mg/m2, and nab-paclitaxel 100 mg/m2, on days 1 and 8, q3w Duration: 3 months
Study: NCT05003531
Drug: IBI112 dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo or dose 2 IBI112 SC
Study: NCT05003531
Drug: IBI112 dose 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo or dose 4 IBI112 SC
Study: NCT05003531
Drug: IBI112 dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo or dose 1 IBI112 SC
Study: NCT05003531
Drug: IBI112 dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo or dose 3 IBI112 SC
Study: NCT05003531
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo SC
Study: NCT05277688
Drug: adjuvant concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: concurrent chemotherapy: cisplatin（DDP） weekly, 40mg/m2, begin with radiation Drug: cisplatin（DDP） weekly; Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy.
Study: NCT05314439
Drug: ION904
Approvals — FDA: no, EMA: no, PMDA: no
Description: ION904 will be administered by SC injection.
Study: NCT05314439
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by SC injection.
Study: NCT05429229
Drug: Humylub PF®
Approvals — FDA: no, EMA: no, PMDA: no
Description: It consists of eye drops without preservatives composed of 0.1% sodium hyaluronate and 0.18% chondroitin sulfate, one drop is applied to each eye every 4 hours for a month.
Study: NCT05607693
Drug: SHR3680 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects start taking SHR3680 tablets 240 mg/dose/day orally on an empty stomach on D1, and the timing of administration daily should be consistent when possible.
Study: NCT05317364
Drug: Placebo vaginal cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream